A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993).

Coleman, R E; Biganzoli, L; Canney, P; Dirix, L; Mauriac, L; Chollet, P; Batter, V; Ngalula-Kabanga, E; Dittrich, C; Piccart, M

Coleman, R E; Biganzoli, L; Canney, P; Dirix, L; Mauriac, L; Chollet, P; Batter, V; Ngalula-Kabanga, E; Dittrich, C; Piccart, M.

Affiliation

Coleman RE; Cancer Research Centre, YCR Department of Clinical Oncology, Weston Park Hospital, Sheffield S10 2SJ, UK. r.e.coleman@sheffield.ac.uk

Eur J Cancer ; 42(7): 882-7, 2006 May.

Article in En | MEDLINE | ID: mdl-16520033

Subject(s)

Antibiotics, Antineoplastic/administration & dosage; Breast Neoplasms/drug therapy; Doxorubicin/administration & dosage; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic/adverse effects; Dose-Response Relationship, Drug; Doxorubicin/adverse effects; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Liposomes/therapeutic use; Middle Aged; Neoplasm Metastasis

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Doxorubicin / Antibiotics, Antineoplastic Type of study: Clinical_trials Limits: Adult / Aged / Aged80 / Female / Humans / Middle aged Language: En Journal: Eur J Cancer Year: 2006 Document type: Article Affiliation country: United kingdom Country of publication: United kingdom

Search on Google

Add to My VHL

XML

PubMed Links